Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have you heard any updates from the company?
I'm grinning from ear to ear, nice post! :)
Does "SHE" have more shares for sale?
What do the experts say today?
WHAT SAY YOU SONG LINK HERE:
The press release suggests the planet Mars.
Quantumkore Innovation Inc. [SBOX] Announces New Patent to Assist Future Construction on Mars
Press Release | 09/12/2022
NEW YORK, NY / ACCESSWIRE / September 12, 2022 / QuantumKore Innovation Inc. announces that it has invented and patented a nuclear-powered extrusion system for use on the Martian surface for the primary purpose of manufacturing bricks, repeated interlocking components that serve as a structural functional basis for rapid manufacturing of habitats, facilities, and other buildings necessary for colonization.
The Board believes that the results of the development team, are examples of excellence in technology, which will lead the company to the next chapters of growth and success.
Feasibility Assessment of Technical Limitations and Challenges to Deployment of a Nuclear-Powered Extrusion System on the Martian Surface
We are invited to the IEEE Aerospace Conference at the Yellowstone Conference Center in Big Sky, Montana, USA (04-11 March 2023)
The International IEEE Aerospace Conference, with AIAA[1] and PHM Society[2] as technical cosponsors, is organized to promote interdisciplinary understanding of aerospace systems, their underlying science and technology, and their applications to government and commercial endeavors. (https://aeroconf.org)
[1] AIAA = American Institute of Aeronautics and Astronautics; is a professional society for the field of aerospace engineering. The AIAA is the U.S. representative on the International Astronautical Federation and the International Council of the Aeronautical Sciences. The AIAA has earned an international reputation as the preeminent publisher of cutting-edge aerospace journals and books, and as the leading source of aerospace industry archives, dating back to the early 1900s; (https://www.aiaa.org)
[2] PHM Society = The Prognostics and Health Management Society; is a non-profit organization dedicated to the advancement of PHM as an engineering discipline; (https://phmsociety.org)
Safe Harbor Statement
This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues as well as any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions.. We have incurred and will continue to incur significant expenses in our expansion of our existing business and there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional expansion of our service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.
Contact Information:
info@qkinnovation.com
SOURCE: QuantumKore Inc.
View source version on accesswire.com:
https://www.accesswire.com/715082/Quantumkore-Innovation-Inc-SBOX-Announces-New-Patent-to-Assist-Future-Construction-on-Mars
Back to News Headlines
Who stated they were selling 100,000 shares?
Are you still holding?
Is $EVFM planning to up-list to Nasdaq?
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
*** Much easier to view it here: https://www.otcmarkets.com/filing/html?id=15747108&guid=5lu-kpannBpCJth#PROXY2022_HTM_i7e47f4b6ac1d498fa8145a1860f599b8_64
Applicable percentages are based on 48,690,590 shares outstanding on March 31, 2022,
The following table sets forth certain information regarding the ownership of the Company’s common stock as of March 31, 2022 by: (i) each director and nominee for director; (ii) each of the executive officers named in the Summary Compensation Table; (iii) all executive officers and directors of the Company as a group; and (iv) all those known by the Company to be beneficial owners of more than five percent of its common stock.
Beneficial Ownership(1)
Beneficial Owner Number of Shares Percent of Total
5% or greater stockholders:
Entities Affiliated with New Enterprise Associates(2)
6,643,704 13.6 %
Entities Affiliated with Avidity Partners Management LP(3)
4,405,000 9.0
Zeneca, Inc.(4)
3,004,554 6.2
Entities Affiliated with Hatteras Venture Partners(5)
2,412,919 5.0
Entities Affiliated with Wellington Management Group LLP(6)
2,869,650 5.9
Entities Affiliated with RA Capital Management, L.P.(7)
2,850,000 5.9
Entities Affiliated with Rock Springs Capital Management LP(8)
2,581,299 5.3
Named executive officers and directors:
Jonathan P. Mow(9)
1,125,251 2.3
John P. Sharp(10)
332,024 *
John S. Lee, M.D., Ph.D.(11)
335,842 *
Edmund P. Harrigan(12)
95,549 *
William D. Humphries(13)
6,222 *
Nancy J. Hutson, Ph.D.(14)
75,678 *
Caroline M. Loewy(15)
68,716 *
Clay B. Thorp(16)
2,508,862 5.1
Alex C. Sapir(17)
28,909 *
Richard A. van den Broek(18)
63,750 *
All executive officers and directors as a group (14 persons)(19)
5,032,926 9.9
*Represents ownership of less than one percent.
(1)This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, the Company believes that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 48,690,590 shares outstanding on March 31, 2022, adjusted as required by rules promulgated by the SEC.
(2)This information has been obtained from a Schedule 13D filed on October 31, 2018 by entities and individuals associated with New Enterprise Associates 13 L.P., or NEA 13, and the Company’s records. Consists of (a) 6,641,634 shares of common stock held directly by NEA 13 and (b) 2,070 shares of common stock held directly by NEA Ventures 2009, L.P., or Ven 2009. NEA Partners 13, L.P., or NEA Partners 13, is the sole general partner of NEA 13 and NEA 13 GP, LTD, or NEA 13 LTD, is the sole general partner of NEA Partners 13. The shares directly held by Ven 2009 are indirectly held by Karen P. Welsh, the general partner of Ven 2009. The principal business address for all entities and individuals affiliated with NEA 13 and Ven 2009 is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093.
(3)This information has been obtained from a Schedule 13G/A filed on February 14, 2022 by entities and individuals associated with Avidity Partners Management LP. Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, David Witzke and Michael Gregory share power to vote, dispose, direct the vote or disposition of 4,405,000 shares of common stock, while Avidity Master Fund LP has the shared power to vote, dispose, direct the vote or disposition of 3,481,766 shares of common stock. David Witzke and Michael Gregory are Managing Members of
22
Avidity Partners Management (GP) LLC, the general partner of Avidity Partners Management LP, and Avidity Capital Partners (GP) LLC, the general partner of Avidity Capital Partners Fund (GP) LP, the general partner of Avidity Master Fund LP. The principal business address for all entities and individuals referenced in this footnote is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201.
(4)This information has been obtained from a Schedule 13D filed on October 29, 2018 by entities and individuals associated with AstraZeneca PLC, or AstraZeneca. Shares beneficially owned consists of 3,004,554 shares directly held by Zeneca Inc., a wholly-owned subsidiary of AstraZeneca, or Zeneca. The principal business address of AstraZeneca is 1 Francis Crick Avenue, Cambridge, CB2 0AA, United Kingdom, and the principal business address of Zeneca is 1800 Concord Pike, Wilmington, Delaware, 19803, United States.
(5)These shares are held by entities and individuals associated with Hatteras Venture Partners. Clay B. Thorp, our Chair, co-founded and serves as general partner of Hatteras Venture Partners. Consists of (a) 1,818,638 shares held by Hatteras Venture Partners III, LP, or HVP III, (b) 162,890 shares held by Hatteras Venture Affiliates III, LP, or HV Affiliates, (c) 415,959 shares held by Venture Capital Multiplier Fund, LP, or Multiplier Fund, and (d) 15,432 shares held by Catalysta Ventures, L.L.C., or Catalysta. Hatteras Venture Advisors III, LLC, or HVA III, is the general partner of HVP III and HV Affiliates. The securities held by HVP III and HV Affiliates are indirectly held by the individual management members of the general partner, HVA III, or the HVA III Managing Members. The HVA III Managing Members are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed and John C. Crumpler. HVA III and the HVA III Managing Members may share voting and dispositive power over the securities directly held by HVP III and HV Affiliates. Catalysta is not under common control with HVA III. The individual management members of Catalysta, or the Catalysta Managing Members, are John C. Crumpler and Clay B. Thorp. The Catalysta Managing Members may share voting and dispositive power over the securities directly held by Catalysta. Hatteras Venture Advisors V, or HVA V, is the general partner of Multiplier Fund. The securities held by Multiplier Fund are indirectly held by the individual management members of the general partner, HVA V, or the HVA V Managing Members. The HVA V Managing Members are John C. Crumpler, Robert A. Ingram, Douglas Reed, Christy Shaffer and Clay B. Thorp. HVA V and the HVA V Managing Members may share voting and dispositive power over the securities directly held by Multiplier Fund. The principal business address for all entities and individuals affiliated with Hatteras Venture Partners is 280 S. Mangum Street, Suite 350 Durham, North Carolina 27701.
(6)This information has been obtained from a Schedule 13G filed on February 4, 2022 by entities and individuals associated with Wellington Management Group LLP. Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP share power to dispose and direct the disposition of 2,869,650 shares of common stock. Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP share power to vote and direct the vote of 2,664,080 shares of common stock. Wellington Management Group LLP is the parent holding company of Wellington Group Holdings LLP, Wellington Investment Advisors LLP and Wellington Management Global Holdings, Ltd., and the following investment advisers (the “Wellington Investment Advisers”): Wellington Management Company LLP, Wellington Management Canada LLC, Wellington Management Singapore Pte Ltd, Wellington Management Hong Kong Ltd, Wellington Management International Ltd, Wellington Management Japan Pte Ltd, Wellington Management Australia Pty Ltd. The shares of common stock beneficially owned by Wellington Management Group LLP are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP. The principal business address for all entities referenced in this footnote is c/o Wellington Management Company LLP, 280 Congress Street, Boston, MA 02210.
(7)This information has been obtained from a Schedule 13G/A filed on February 14, 2022 by entities and individuals associated with RA Capital Management, L.P (“RA Capital”). Consists of 2,850,000 shares of common stock held directly by RA Capital Healthcare Fund, L.P. (the “Fund”). RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner of the securities held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of these securities. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners of the securities beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim ownership of these securities. The principal business address for all entities and individuals referenced in this footnote is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116.
(8)This information has been obtained from a Schedule 13G/A filed on February 15, 2022 by entities associated with Rock Springs Capital Management LP (“RSCM”). Consists of (i) 2,375,000 shares of common stock directly beneficially owned by Rock Springs Capital Master Fund LP (“Master Fund”) and (ii) 206,299 shares of common stock directly beneficially owned by Four Pines Master Fund LP (“Four Pines”). RSCM serves as the investment manager to each of the Master Fund and Four Pines. Rock Springs Capital LLC is the general partner of RSCM. The principal business address for RSCM and RSC is 650 South Exeter, Suite 1070, Baltimore, MD 21202, and the principal business address for Master Fund is c/o Walkers Corporate Limited, Cayman Corporate Centre, 27 Hospital Road, George Town, Grand Cayman, KY1-9008, Cayman Islands.
(9)Consists of (a) 51,199 shares of common stock held by the Mow Trust dated April 17, 2008, (b) 121,584 shares of common stock held directly by Mr. Mow and (c) 952,468 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022. Mr. Mow and his wife Diana Mow are joint trustees of the Mow Trust dated April 17, 2008 and share voting and dispositive power for such shares.
23
(10) Consists of (a) 59,741 shares of common stock and (b) 272,283 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
(11) Consists of 335,842 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
(12) Consists of (a) 6,000 shares of common stock and (b) 89,549 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
(13) Consists of 6,222 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
(14) Consists of (a) 33,760 shares of common stock, (b) 4,000 shares of common stock held in an individual retirement account for the benefit of Dr. Hutson and (c) 37,918 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
(15) Consists of 68,716 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
(16) Consists of (a) 32,943 shares of common stock held by Mr. Thorp and (b) 63,000 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022. Also consists of (a) 1,818,638 shares of common stock held directly by Hatteras Venture Partners III, LP, or HVP III, (b) 162,890 shares of common stock held directly by Hatteras Venture Affiliates III, LP, or HV Affiliates, (c) 415,959 shares of common stock held directly by Venture Capital Multiplier Fund, or Multiplier Fund, and (d) 15,432 shares of common stock held directly by Catalysta Ventures, L.L.C., or Catalysta. Hatteras Venture Advisors III, LLC, or HVA III, is the general partner of HVP III and HV Affiliates. The securities held directly by HVP III and HV Affiliates are indirectly held by HVA III. Mr. Thorp is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III and HV Affiliates. Hatteras Venture Advisors V, LLC, or HVA V, is the general partner of Multiplier Fund. The securities held directly by Multiplier Fund are indirectly held by HVA V. Mr. Thorp is a manager of HVA V and may be deemed to share voting and dispositive power with regard to the securities held by Multiplier Fund. Mr. Thorp is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta.
(17) Consists of 28,909 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
(18) Consists of 63,750 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
(19) Consists of (a) 2,756,097 shares of common stock and (b) 2,276,829 shares of common stock issuable upon the exercise of options within 60 days of March 31, 2022.
https://www.otcmarkets.com/filing/html?id=15747108&guid=5lu-kpannBpCJth#PROXY2022_HTM_i7e47f4b6ac1d498fa8145a1860f599b8_64
I'm new here, what is the scoop with this company?
1million shares traded, very large buys at ask.
Date/Time Price Shares Exch/Mkt
05/04/2023 11:41:00 EDT 0.0007 200 OTCBB
05/04/2023 11:36:22 EDT 0.0011 190000 OTCBB
05/04/2023 11:34:59 EDT 0.0011 159246 OTCBB
05/04/2023 11:34:38 EDT 0.001 500000 OTCBB
05/04/2023 11:34:38 EDT 0.001 6425 OTCBB
05/04/2023 11:34:37 EDT I 0.0009 10 OTCBB
05/04/2023 11:34:37 EDT I 0.0008 50 OTCBB
05/04/2023 11:34:37 EDT I 0.0008 12 OTCBB
05/03/2023 15:03:29 EDT I 0.0007 10 OTCBB
05/03/2023 14:04:06 EDT 0.0007 6461 OTCBB
the dilution is very strong with this one.
Just buy more shares at the sale price today.
Did everyone see the alarming 8-K published Friday after hours?
On March 28, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of SANUWAVE Health, Inc. (the “Company”) after discussion with management concluded that the interim financial statements contained in the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022 (the “Form 10-Qs”) should no longer be relied upon for the reasons summarized below.
https://www.otcmarkets.com/filing/html?id=16534150&guid=bwm-ke_QP5kVV3h
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 28, 2023
SANUWAVE Health, Inc.
(Exact name of registrant as specified in its charter)
Nevada
000-52985
20-1176000
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
11495 Valley View Road, Eden Prairie, Minnesota
55344
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code
(770) 419-7525
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
?
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
?
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
N/A
N/A
N/A
Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 4.02
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.
On March 28, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of SANUWAVE Health, Inc. (the “Company”) after discussion with management concluded that the interim financial statements contained in the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022 (the “Form 10-Qs”) should no longer be relied upon for the reasons summarized below.
In connection with preparing its financial statements for the year ended December 31, 2022, the Company identified several accounting misstatements and as such is restating the interim financial statements in the Form 10-Qs to correct (i) an inventory conversion error during the quarter ended September 30, 2022; (ii) a failure to recognize (a) professional fee invoices during each of the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022, (b) advisory shares during the quarter ended June 30, 2022; and (c) interest expense on the Senior Secured Promissory Note Payable issued by the Company to NH Expansion Credit Fund Holdings LP during the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022; and (iii) improper recording of a financing lease arrangement during the quarters ended March 31, 2022 and June 30, 2022.
The Company and its advisors completed the annual review, and the Company will file the restated financial statements as of March 31, 2022, June 30, 2022 and September 30, 2022 and for the three months ended March 31, 2022, the three and six months ended June 30, 2022 and the three and nine months ended September 30, 2022 in its Annual Report on Form 10-K for the year ending December 31, 2022.
The Audit Committee and Company management have discussed the matters disclosed on this Current Report on Form 8-K with the Company’s independent registered public accounting firm, Marcum LLP.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SANUWAVE HEALTH, INC.
Dated: March 31, 2023
By:
/s/ Toni Rinow
Name:
Toni Rinow
Title:
Chief Financial Officer
@NewNTAC From $NTAC latest 10-Q "1 Million Shares Common Restricted that will be cancelled & returned to treasury, reducing outstanding total shares after the completion of the process." https://bit.ly/3mBFXMj
$NTAC says absolutely
— New Technology Acquisition Holdings Inc. (NTAC) (@NewNTAC) March 8, 2023
Let them have it !
SEC-form shows company employees selling shares in open-market. Their salaries are being paid with common shares which means that WE have the responsibility of paying for their nine-to-five job.
"Remarks: The Common Shares were issued by the Issuer to the Reporting Person pursuant to Rule 16b-3(d)(1) in payment of salary in lieu of cash payment."
https://www.otcmarkets.com/filing/html?id=16365301&guid=jX7-kKfyqmX7dth
The company is to blame.
Shell Risk Removed $MRGE
Stock Scan
@stockscan01
$MRGE
?? MRGE
?? 0,0011
??? Shell Risk Removed
2:57 AM · Feb 6, 2023
·
32 Views
$MRGE
— Stock Scan (@stockscan01) February 6, 2023
🚨 MRGE
💰 0,0011
🟡❕ Shell Risk Removed
White Lion equals a license for $UEEC company to sell A LOT of shares. Feels like dilution.
What is the scoop for today folks?
Did
this ticker show up in your DD Amanda scanner?
650K market seller into low bids! Was that one of us or insiders that sold 650,000 shares today?
Date/Time Price Shares Exch/Mkt
01/04/2023 15:43:43 EST 0.04 20000 OTCBB
01/04/2023 15:43:41 EST 0.04 10000 OTCBB
01/04/2023 15:43:41 EST 0.04 10000 OTCBB
01/04/2023 15:39:03 EST 0.035 484700 OTCBB
01/04/2023 15:38:59 EST 0.035 10000 OTCBB
01/04/2023 15:38:57 EST 0.035 10000 OTCBB
01/04/2023 15:38:52 EST 0.0525 25300 OTCBB
01/04/2023 15:38:46 EST 0.054 20000 OTCBB
01/04/2023 15:38:44 EST 0.055 50000 OTCBB
01/04/2023 15:38:41 EST 0.056 10000 OTCBB
01/04/2023 15:38:26 EST 0.058 25000 OTCBB
01/04/2023 15:38:24 EST 0.065 15000 OTCBB
01/04/2023 10:42:51 EST I 0.067 50 OTCBB
01/03/2023 15:37:49 EST 0.0675 10000 OTCBB
01/03/2023 13:24:22 EST 0.067 10000 OTCBB
01/03/2023 13:01:57 EST 0.067 2200 OTCBB
01/03/2023 11:22:57 EST 0.065 9500 OTCBB
01/03/2023 10:16:56 EST 0.065 10000 OTCBB
01/03/2023 9:30:12 EST 0.065 500 OTCBB
01/03/2023 9:30:03 EST 0.069 1288 OTCBB
01/03/2023 9:30:01 EST 0.069 2900 OTCBB
12/30/2022 15:42:47 EST 0.065 10000 OTCBB
12/30/2022 15:08:40 EST 0.067 5275 OTCBB
12/30/2022 13:50:42 EST 0.067 5000 OTCBB
12/30/2022 9:35:37 EST 0.067 144 OTCBB
12/30/2022 9:35:37 EST 0.067 1300 OTCBB
12/30/2022 9:35:37 EST 0.067 1000 OTCBB
12/29/2022 14:45:55 EST 0.069 10000 OTCBB
12/29/2022 14:32:05 EST 0.069 500 OTCBB
12/29/2022 14:11:04 EST 0.069 300 OTCBB
Thanks. Is PMPG still expected to-submit-updated-financial-documents?
I'm invested in this PMPG. Which others do you suggest?
I'm not sure why, but my NITE (TD Ameritrade) bids didn't fill when those cheapies were dumped into the low bid at .5045 2.5k + 13.6k. Did you get those cheapies? Which broker do you use?
Date/Time Price Shares Exch/Mkt
12/28/2022 15:07:00 EST 0.59 7000 OTCBB
12/28/2022 12:18:08 EST 0.597 500 OTCBB
12/28/2022 11:46:52 EST 0.5954 4400 OTCBB
12/28/2022 11:46:51 EST 0.596 1000 OTCBB
12/28/2022 11:46:47 EST 0.596 1000 OTCBB
12/28/2022 11:46:47 EST 0.596 2100 OTCBB
12/28/2022 11:36:48 EST 0.583 250 OTCBB
12/28/2022 10:27:59 EST 0.57 1000 OTCBB
12/28/2022 10:02:18 EST 0.56 17000 OTCBB
12/28/2022 9:32:56 EST 0.5045 13604 OTCBB
12/28/2022 9:32:55 EST 0.5045 2500 OTCBB
12/28/2022 9:32:35 EST 0.54 1000 OTCBB
12/28/2022 9:32:31 EST 0.54 2100 OTCBB
12/28/2022 9:32:27 EST 0.55 1000 OTCBB
12/28/2022 9:32:24 EST 0.55 1000 OTCBB
12/28/2022 9:32:20 EST 0.57 2296 OTCBB
12/28/2022 9:32:14 EST 0.575 1000 OTCBB
12/27/2022 15:52:25 EST I 0.59 8 OTCBB
12/27/2022 13:21:14 EST 0.59 5000 OTCBB
12/27/2022 13:21:14 EST 0.59 600 OTCBB
12/27/2022 12:28:29 EST 0.5835 1058 OTCBB
12/27/2022 12:05:08 EST 0.5888 200 OTCBB
12/27/2022 11:52:42 EST 0.5914 2000 OTCBB
12/27/2022 9:34:43 EST 0.5975 2000 OTCBB
12/27/2022 9:30:09 EST 0.57 1000 OTCBB
12/23/2022 15:27:06 EST 0.55 2000 OTCBB
12/23/2022 10:30:31 EST 0.57 1000 OTCBB
12/23/2022 10:30:18 EST 0.57 500 OTCBB
12/23/2022 10:30:15 EST 0.58 1000 OTCBB
12/23/2022 10:30:11 EST 0.5825 1000 OTCBB
The selling likely from company insiders and White-Lion.
United Health Products Announces Equity Financing Agreement and Provides Corporate Update
September 06, 2022 10:11 ET | Source: United Health Products, Inc.
...
Mesquite, NV, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- United Health Products, Inc. (OTCPK: UEEC), (UHP) today announced that it has entered into a common stock purchase agreement to sell up to $10 million of shares to White Lion Capital, LLC (White Lion), a California-based institutional investor. Under the terms of the purchase agreement, UHP will have the right, in its sole discretion, to sell shares to White Lion over a 36-month term. Any common stock sold to White Lion will occur at a purchase price derived from the prevailing market prices of the company’s common stock at the time of each sale. The company will control the timing and amount of any shares of common stock sold to White Lion, and White Lion is obligated to make purchases at quantities and prices in accordance with the purchase agreement when requested. UHP's ability to make common stock purchase requests is subject to customary limitations and conditions in the stock purchase agreement, including the registration of the resale of the shares on behalf of White Lion under a registration statement to be filed with the SEC on Form S-3.
Separately, the previously announced payments of approximately $1 million to be received by UHP from a former executive of the company have been modified such that the company has received approximately $200,000 and 2,000,000 shares of its common stock are being returned to the company. These shares will be available for reissuance under the above agreement with White Lion.
The proceeds of any sale of common stock to White Lion will be used for general corporate purposes including the establishment of a manufacturing operation for the company’s HemoStyp hemostatic gauze product and the completion of all remaining elements of the FDA Premarket Approval application, and to advance the development of powder and gel formats of the company’s patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent.
Regarding the company’s previously disclosed legal action relating to the audit of its 2017 financial statements, on August 31, 2022 the company and the defendant entered into a settlement agreement under which, among other provisions, UHP will receive a cash payment this month.
Brian Thom, UHP’s Chief Executive Officer, commented: “The resolution of this outstanding litigation, combined with the White Lion transaction and the settlement of payments from our former executive, will provide the company with over $1 million in capital to advance its business plan without diluting shareholders.”
Regarding the company’s FDA PMA application process, UHP continues to work with its intended manufacturing partner and its regulatory consultant, Regulatory Compliance Associates, to establish production and complete all necessary documentation. UHP is auditing the production facility as well as its documentation and employee training processes, among other elements of the partner’s operations. The company’s manufacturing equipment will commence production, allowing for the completion of Standard Operating Procedure and Design Control documentation, and the development of the Design Transfer process that will transfer detailed product design information to the manufacturing partner. It is anticipated that the completion of the audit process, establishment and inspection of gauze production, drafting of associated documentation, and testing of product to ensure conformance with previous product specifications will be completed within 60 days. In the interim, the company will continue to provide updates on achievement of milestones in this process.
There can be no assurance that the company’s PMA application will be approved.
Investor relations:
info@unitedhealthproductsinc.com
475.755.1005
Philippe Niemetz
212 344-6464
p.niemetz@panconsultants.com
About United Health Products -- United Health Products develops, manufactures and markets HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and consumer markets, and is focused on gaining approval to access the human surgical market.
For more information on UHP visit: www.unitedhealthproductsinc.com or contact the company at info@unitedhealthproductsinc.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
.2200 5575, did you get enough?
Looks like today they will fill your .22
Interesting weekend anticipation from the buyers today.
Let's see the NITE 300k bidder buy_at_market_offers!
is this one coming back to life?
Whomever is routing NITE, they are dumping heavy amounts of shares. Either a shareholder taking the exit or dilution.
Massive bid whack dumping caught me by surprise. I thought we were making good progress with the price action, until 15 minutes ago... massive dumping into the low bids.
Date/Time Price Shares Exch/Mkt
12/06/2022 15:19:23 EST 0.278 500 OTCBB
12/06/2022 15:14:46 EST 0.22 18425 OTCBB
12/06/2022 15:14:46 EST 0.22 1841 OTCBB
12/06/2022 15:14:45 EST 0.22 5000 OTCBB
12/06/2022 15:14:44 EST 0.23 44100 OTCBB
12/06/2022 15:14:35 EST 0.279 300 OTCBB
12/06/2022 15:14:34 EST 0.235 2500 OTCBB
12/06/2022 15:14:31 EST 0.2665 200 OTCBB
12/06/2022 15:14:25 EST 0.235 5800 OTCBB
12/06/2022 15:14:19 EST 0.2351 2500 OTCBB
12/06/2022 15:14:18 EST 0.235 1500 OTCBB
12/06/2022 15:14:18 EST 0.24 2500 OTCBB
12/06/2022 15:14:07 EST 0.245 25000 OTCBB
12/06/2022 15:14:04 EST 0.24 3000 OTCBB
12/06/2022 15:14:04 EST 0.245 25000 OTCBB
12/06/2022 15:14:01 EST 0.2461 2498 OTCBB
12/06/2022 15:13:56 EST 0.2451 2500 OTCBB
12/06/2022 15:13:50 EST 0.25 30000 OTCBB
12/06/2022 15:13:49 EST 0.245 2000 OTCBB
12/06/2022 15:13:49 EST 0.25 2500 OTCBB
12/06/2022 15:13:47 EST 0.2501 2500 OTCBB
12/06/2022 15:10:47 EST 0.2573 1740 OTCBB
12/06/2022 15:10:47 EST 0.255 2500 OTCBB
12/06/2022 15:06:13 EST 0.25 10000 OTCBB
12/06/2022 15:03:15 EST 0.2575 100 OTCBB
12/06/2022 13:56:18 EST 0.245 2500 OTCBB
12/06/2022 13:32:18 EST 0.2575 100 OTCBB
12/06/2022 10:43:08 EST 0.26 100 OTCBB
12/06/2022 10:35:48 EST 0.24 33804 OTCBB
12/06/2022 10:35:36 EST 0.2398 2500 OTCBB
We're all learning here.
The longs on this board appear to be the most patient investors in OTC land.
I had bids between the spread .60 - .65 when that 3k sold at .6003, but I didn't get any fills using NITE in this case. I'm curious about how this OTC trading works, how do they decide whose bids get filled?
which broker do you use?
Excellent news, see you much higher!
Expecting positive news right?